Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Poststroke Lung Infection by Opportunistic Commensal Bacteria Is Not Mediated by Their Expansion in the Gut Microbiota

  • Díaz-Marugan, Laura|||0000-0002-7589-2547
  • Gallizioli, Mattia|||0000-0001-9245-914X
  • Márquez-Kisinousky, Leonardo
  • Arboleya, Silvia|||0000-0002-6155-5822
  • Mastrangelo, Annalaura|||0000-0003-2650-0444
  • Ruiz-Jaén, Francisca
  • Pedragosa, Jordi|||0000-0001-8493-4545
  • Casals-Pascual, Climent|||0000-0002-0867-8954
  • Morales, Francisco Javier
  • Ramos-Romero, Sara|||0000-0002-9293-4454
  • Traserra, Sara
  • Justicia, Carles|||0000-0003-0969-6158
  • Gueimonde, Miguel|||0000-0002-0192-901X
  • Jiménez Farrerons, Marcel|||0000-0002-6602-7332
  • Torres, Josep Lluís|||0000-0002-5072-8265
  • Urra, Xabier|||0000-0002-4763-5252
  • Chamorro, Ángel|||0000-0003-0493-5340
  • Sancho, David
  • de los Reyes-Gavilán, Clara G.|||0000-0001-9396-6311
  • Miró-Mur, Francesc|||0000-0003-3936-2693
  • Planas, Anna Maria|||0000-0002-6147-1880
Background: Respiratory and urinary tract infections are frequent complications in patients with severe stroke. Stroke-associated infection is mainly due to opportunistic commensal bacteria of the microbiota that may translocate from the gut. We investigated the mechanisms underlying gut dysbiosis and poststroke infection. Methods: Using a model of transient cerebral ischemia in mice, we explored the relationship between immunometabolic dysregulation, gut barrier dysfunction, gut microbial alterations, and bacterial colonization of organs, and we explored the effect of several drug treatments. Results: Stroke-induced lymphocytopenia and widespread colonization of lung and other organs by opportunistic commensal bacteria. This effect correlated with reduced gut epithelial barrier resistance, and a proinflammatory sway in the gut illustrated by complement and nuclear factor-κB activation, reduced number of gut regulatory T cells, and a shift of gut lymphocytes to γδT cells and T helper 1/T helper 17 phenotypes. Stroke increased conjugated bile acids in the liver but decreased bile acids and short-chain fatty acids in the gut. Gut fermenting anaerobic bacteria decreased while opportunistic facultative anaerobes, notably Enterobacteriaceae, suffered an expansion. Anti-inflammatory treatment with a nuclear factor-κB inhibitor fully abrogated the Enterobacteriaceae overgrowth in the gut microbiota induced by stroke, whereas inhibitors of the neural or humoral arms of the stress response were ineffective at the doses used in this study. Conversely, the anti-inflammatory treatment did not prevent poststroke lung colonization by Enterobacteriaceae. Conclusions: Stroke perturbs homeostatic neuro-immuno-metabolic networks facilitating a bloom of opportunistic commensals in the gut microbiota. However, this bacterial expansion in the gut does not mediate poststroke infection.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fgr kinase is required for proinflammatory macrophage activation during diet-induced obesity

  • Acín-Pérez, Rebeca
  • Iborra, Salvador
  • Martí-Mateos, Yolanda
  • Cook, Emma C. L.
  • Conde-Garrosa, Ruth
  • Petcherski, Anton
  • Muñoz, María del Mar
  • Martínez de Mena, Raquel
  • Krishnan, Karthickeyan Chella
  • Jiménez, Concepción
  • Bolaños, Juan P.
  • Laakso, Markku
  • Lusis, Aldons J.
  • Shirihai, Orian S.
  • Sancho, David
  • Enríquez, José Antonio
Proinflammatory macrophages are key in the development of obesity. In addition, reactive oxygen species (ROS), which activate the Fgr tyrosine kinase, also contribute to obesity. Here we show that ablation of Fgr impairs proinflammatory macrophage polarization while preventing high-fat diet (HFD)-induced obesity in mice. Systemic ablation of Fgr increases lipolysis and liver fatty acid oxidation, thereby avoiding steatosis. Knockout of Fgr in bone marrow (BM)-derived cells is sufficient to protect against insulin resistance and liver steatosis following HFD feeding, while the transfer of Fgr-expressing BM-derived cells reverts protection from HFD feeding in Fgr-deficient hosts. Scavenging of mitochondrial peroxides is sufficient to prevent Fgr activation in BM-derived cells and HFD-induced obesity. Moreover, Fgr expression is higher in proinflammatory macrophages and correlates with obesity traits in both mice and humans. Thus, our findings reveal the mitochondrial ROS–Fgr kinase as a key regulatory axis in proinflammatory adipose tissue macrophage activation, diet-induced obesity, insulin resistance and liver steatosis., The METSIM study was supported by grants from the Academy of Finland (no. 321428), Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular Research, Centre of Excellence of Cardiovascular and Metabolic Diseases and the Academy of Finland (to M.L.). Work in the laboratory of J.A.E. is funded by the CNIC and a grant by Ministerio de Ciencia, Innovación e Universidades (MICINN), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER; SAF2015-65633-R and RTI2018-099357-B-I00), the EU (UE0/MCA317433), the Biomedical Research Networking Center on Frailty and Healthy Ageing (CIBERFES-ISCiii) and the HFSP agency (RGP0016/2018). Work in the laboratory of D.S. is funded by the CNIC; the European Research Council (ERC-2016-Consolidator Grant 725091); the European Commission (635122-PROCROP H2020); MICINN, AEI and FEDER (SAF2016-79040-R and PID2019-108157RB); Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); FIS-Instituto de Salud Carlos III, MICINN and FEDER (RD16/0015/0018-REEM); the Acteria Foundation; Atresmedia (Constantes y Vitales prize); and Fundació La Marató de TV3 (201723). Work in the laboratory of O.S.S. is funded by National Institutes of Health (NIH; R01 DK099618-05, R01 CA232056-01, R21AG060456-01 and R21 AG063373-01) and the American Diabetes Association (1-19-IBS-049). Work in laboratory of A.J.L. was supported by NIH-PO1HL028481 and NIH-R01DK117850 (A.J.L.). Work in the laboratory of M.L. was funded by the Academy of Finland. Work in the laboratory of J.P.B. was funded by Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2016-78114-R and RED2018‐102576‐T), Instituto de Salud Carlos III (CB16/10/00282), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA and Fundación Ramón Areces. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), MICINN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). K.C.K. is funded by NIH-K99 DK120875 and AHA Fellowship 18POST33990256. S.I. is funded by RYC-2016-19463 and RTI2018-094484-B-I00.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

  • Fresno, Carlos del
  • García-Arriaza, Juan
  • Martínez-Cano, Sarai
  • Heras-Murillo, Ignacio
  • Jarit-Cabanillas, Aitor
  • Amores-Iniesta, Joaquín
  • Brandi, Paola
  • Dunphy, Gillian
  • Suay-Corredera, Carmen
  • Pricolo, Maria Rosaria
  • Vicente, Natalia
  • López-Perrote, Andrés
  • Cabezudo, Sofía
  • González-Corpas, Ana
  • Llorca, Óscar
  • Alegre-Cebollada, Jorge
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Esteban, Mariano
  • Sancho, David
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity., CF was supported by AECC Foundation (INVES192DELF) and is currently funded by the Miguel Servet program (ID: CP20/00106) (ISCIII). IH-M receives the support of a fellowship from la Caixa Foundation (ID 100010434, fellowship code: LCF/BQ/IN17/11620074) and from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 713673. AJ-C is a postgraduate fellow of the City Council of Madrid at the Residencia de Estudiantes (2020–2021). GD is supported by an European Molecular Biology Organization (EMBO) Long-term fellowship (ALTF 379-2019). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. Project number 892965. OL and JA-C acknowledge Comunidad de Madrid (Tec4Bio-CM, S2018/NMT-4443, FEDER). Work in OL laboratory was funded by CNIO with the support of the projects Y2018/BIO4747 and P2018/NMT4443 from Comunidad de Madrid and co-funded by the European Social Fund and the European Regional Development Fund. The CNIO is supported by the Instituto de Salud Carlos III (ISCIII). Work at CNB and CISA is funded by the Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII), Fondo COVID-19 grant COV20/00151, and Fondo Supera COVID-19 (Crue Universidades-Banco Santander) (to JG-A). Work in the DS laboratory is funded by the CNIC; by the European Research Council (ERC-2016-Consolidator Grant 725091); by Agencia Estatal de Investigación (PID2019-108157RB); by Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); by Fondo Solidario Juntos (Banco Santander); by a research agreement with Inmunotek S.L.; and by Fundació La Marató de TV3 (201723). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICINN, and the Pro CNIC Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

  • Cueto, Francisco J.
  • Fresno, Carlos del
  • Brandi, Paola
  • Combes, Alexis J.
  • Hernández-García, Elena
  • Sánchez-Paulete, Alfonso R.
  • Enamorado, Michel
  • Bromley, Christian P
  • Gómez, Manuel José
  • Conde-Garrosa, Ruth
  • Mañes, Santos
  • Zelenay, Santiago
  • Melero, Ignacio
  • Iborra, Salvador
  • Krummel, Matthew F.
  • Sancho, David
[Background]: Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricted to cDC1s. DNGR-1 has been involved in both cross-presentation of dead cell-associated antigens and processes of disease tolerance, but its role in antitumor immunity has not been clarified yet., [Methods]: B16 and MC38 tumor cell lines were inoculated subcutaneously into wild-type (WT) and DNGR-1-deficient mice. To overexpress Flt3L systemically, we performed gene therapy through the hydrodynamic injection of an Flt3L-encoding plasmid. To characterize the immune response, we performed flow cytometry and RNA-Seq of tumor-infiltrating cDC1s., [Results]: Here, we found that cross-presentation of tumor antigens in the steady state was DNGR-1-independent. However, on Flt3L systemic overexpression, tumor growth was delayed in DNGR-1-deficient mice compared with WT mice. Of note, this protection was recapitulated by anti-DNGR-1-blocking antibodies in mice following Flt3L gene therapy. This improved antitumor immunity was associated with Batf3-dependent enhanced accumulation of CD8+ T cells and cDC1s within tumors. Mechanistically, the deficiency in DNGR-1 boosted an Flt3L-induced specific inflammatory gene signature in cDC1s, including Ccl5 expression. Indeed, the increased infiltration of cDC1s within tumors and their protective effect rely on CCL5/CCR5 chemoattraction. Moreover, FLT3LG and CCL5 or CCR5 gene expression signatures correlate with an enhanced cDC1 signature and a favorable overall survival in patients with cancer. Notably, cyclophosphamide elevated serum Flt3L levels and, in combination with the absence of DNGR-1, synergized against tumor growth., [Conclusion]: DNGR-1 limits the accumulation of tumor-infiltrating cDC1s promoted by Flt3L. Thus, DNGR-1 blockade may improve antitumor immunity in tumor therapy settings associated to high Flt3L expression., FJC was the recipient of a PhD ‘La Caixa’ fellowship (LCF/BQ/ES14/10320011). CdF is supported by AECC Foundation (INVES192DELF) and Miguel Servet program (ISCIII). CB is funded by the National Institute for Health Research Manchester Biomedical Research Center. Work in the DS laboratory is funded by the CNIC; by the European Research Council (ERC-2016-Consolidator Grant 725091); by the European Commission (635122-PROCROP H2020); by Ministerio de Ciencia e Innovación (MICINN), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (SAF2016-79040-R); by AEI (PID2019-108157RB); by Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); by FIS-Instituto de Salud Carlos III, MICINN and FEDER (RD16/0015/0018-REEM); by Acteria Foundation; by Atresmedia (Constantes y Vitales prize) and by Fundació La Marató de TV3 (201723). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICINN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (referencia del instituto). Por ejemplo: With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

  • Lázaro-Gorines, Rodrigo
  • Pérez Ramírez, Patricia
  • Heras-Murillo, Ignacio
  • Adán-Barrientos, Irene
  • Albericio, Guillermo
  • Astorgano, David
  • Flores, Sara
  • Luczkowiak, Joanna
  • Labiod, Nuria
  • Harwood, Seandean Lykke
  • Segura-Tudela, Alejandro
  • Rubio-Pérez, Laura
  • Nugraha, Yudhi
  • Shang, Xiaoran
  • Li, Yuxing
  • Alfonso, Carlos
  • Adipietro, Kaylin A.
  • Abeyawardhane, Dinendra L.
  • Navarro, Rocío
  • Compte, Marta
  • Yu, Wenbo
  • MacKerell Jr., Alexander D.
  • Sanz, Laura
  • Weber, David J.
  • Blanco, Francisco J.
  • Esteban, Mariano
  • Pozharski, Edwin
  • Godoy-Ruiz, Raquel
  • Muñoz, Inés G.
  • Delgado, Rafael
  • Sancho, David
  • García-Arriaza, Juan
  • Álvarez-Vallina, Luis
17 p.-4 fig., Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS-CoV-2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross-priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT, are first generated by grafting an anti-RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo-EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high-avidity neutralizing interaction. Then, by C-terminal fusion of an anti-DNGR-1 scFv to TNT, the bispecific trimerbody TNTDNGR-1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross-priming. Therapeutic administration of TNTDNGR-1, but not TNT, protects K18-hACE2 mice from a lethal SARS-CoV-2 infection, boosting virus-specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus-neutralizing antibody activity and demonstrate the therapeutic potential of the Fc-free strategy that can be used advantageously to provide both immediate and long-term protection against SARS-CoV-2 and other viral infections., SARS-CoV-2 B.1.351 and B.1.167.2 viruses used in this study were obtained through the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 653316. SARS-CoV-2 B.1 (MAD6 isolate) was kindly provided by José M. Honrubia and Luis Enjuanes (CNB-CSIC, Madrid, Spain). The authors thank Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC) (Valdeolmos, Madrid, Spain) for the BSL-3 facilities. Research in LA-V laboratory was funded by the BBVA Foundation (Ayudas Fundación BBVA a Equipos de Investigación Científica SARS-CoV-2 y COVID-19); the MCIN/AEI/10.13039/501100011033 (PID2020-117323RB-I00 and PDC2021-121711-I00), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (DTS20/00089), partially supported by the ERDF, the Spanish Association Against Cancer (AECC 19084); the CRIS Cancer Foundation (FCRIS-IFI-2018 and FCRIS-2021-0090), the Fundación Caixa-Health Research (HR21-00761 project IL7R_LungCan), and the Comunidad de Madrid (P2022/BMD-7225 NEXT_GEN_CART_MAD-CM). Work in the DS laboratory was funded by the CNIC; the European Union's Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; MCIN/AEI/10.13039/501100011033 (PID2019-108157RB); Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); Atresmedia (Constantes y Vitales prize); Fondo Solidario Juntos (Banco Santander); and “La Caixa” Foundation (LCF/PR/HR20/00075). The CNIC was supported by the ISCIII, the MCIN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033). Research in RD laboratory was supported by the ISCIII (PI2100989) and CIBERINFEC; the European Commission Horizon 2020 Framework Programme (grant numbers 731868 project VIRUSCAN FETPROACT-2016, and 101046084 project EPIC-CROWN-2); and the Fundación Caixa-Health Research (grant number HR18-00469 project StopEbola). Research in CNB-CSIC laboratory was funded by Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant, CIBERINFEC, and Spanish Research Council (CSIC) grant 202120E079 (to J.G.-A.), CSIC grant 2020E84 (to M.E.), MCIN/AEI/10.13039/501100011033 (PID2020-114481RB-I00 to J.G-A. and M.E.), and by the European Commission-NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) to J.G.-A. and M.E. Work in the CIB-CSIC laboratory was supported by MCIN/AEI/10.13039/501100011033 (PID2019-104544GB-I00 and 2023AEP105 to CA, and PID2020-113225GB-I00 to F.J.B.). Cryo-EM data were collected at the Maryland Center for Advanced Molecular Analyses which was supported by MPOWER (The University of Maryland Strategic Partnership). I.H.-M. receives the support of a fellowship from la Caixa Foundation (ID 100010434, fellowship code: LCF/BQ/IN17/11620074) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 71367. L.R.-P. was supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expression of HMGCS2 in intestinal epithelial cells is downregulated in inflammatory bowel disease associated with endoplasmic reticulum stress

  • Martín-Adrados, Beatriz
  • Wculek, Stefanie K.
  • Fernández-Bravo, Sergio
  • Torres-Ruiz, Raúl
  • Valle-Noguera, Ana
  • Gómez-Sánchez, María José
  • Hernández-Walias, José Carlos
  • Moraes Ferreira, Frederico
  • Corraliza, Ana María
  • Sancho, David
  • Esteban, Vanesa
  • Rodríguez-Perales, Sandra
  • Cruz-Adalia, Aránzazu
  • Nakaya, Helder I.
  • Salas, Azucena
  • Bernardo, David
  • Campos-Martín, Yolanda
  • Martínez-Zamorano, Elena
  • Muñoz-López, Diego
  • Gómez del Moral, Manuel
  • Cubero, Francisco Javier
  • Blumberg, Richard S.
  • Martínez-Naves, Eduardo
[Introduction]: The Unfolded Protein Response, a mechanism triggered by the cell in response to Endoplasmic reticulum stress, is linked to inflammatory responses. Our aim was to identify novel Unfolded Protein Response-mechanisms that might be involved in triggering or perpetuating the inflammatory response carried out by the Intestinal Epithelial Cells in the context of Inflammatory Bowel Disease. [Methods]: We analyzed the transcriptional profile of human Intestinal Epithelial Cell lines treated with an Endoplasmic Reticulum stress inducer (thapsigargin) and/or proinflammatory stimuli. Several genes were further analyzed in colonic biopsies from Ulcerative Colitis patients and healthy controls. Lastly, we generated Caco-2 cells lacking HMGCS2 by CRISPR Cas-9 and analyzed the functional implications of its absence in Intestinal Epithelial Cells. [Results]: Exposure to a TLR ligand after thapsigargin treatment resulted in a powerful synergistic modulation of gene expression, which led us to identify new genes and pathways that could be involved in inflammatory responses linked to the Unfolded Protein Response. Key differentially expressed genes in the array also exhibited transcriptional alterations in colonic biopsies from active Ulcerative Colitis patients, including NKG2D ligands and the enzyme HMGCS2. Moreover, functional studies showed altered metabolic responses and epithelial barrier integrity in HMGCS2 deficient cell lines. [Conclusion]: We have identified new genes and pathways that are regulated by the Unfolded Protein Response in the context of Inflammatory Bowel Disease including HMGCS2, a gene involved in the metabolism of Short Chain Fatty Acids that may have an important role in intestinal inflammation linked to Endoplasmic Reticulum stress and the resolution of the epithelial damage., This work was supported by grants from Ministerio de Ciencia e Innovación (MCIN) from Spain [SAF2016-78711R and PID202-11794 to EM-N and FJC]; Comunidad de Madrid [B2017/BMD-3727 to EM-N and FJC]; Comunidad de Madrid (REACT-UE, ANTICIPA-CM Ref. PR38/21-24) to E.M-N and HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 to FJC the European Union’s Horizon 2020 research and innovation program [ERC-2016-Consolidator Grant 725091 to DS]; MCIN/AEI/10.13039/501100011033 [PID2019-108157RB to DS]; la Caixa Foundation (ID 100010434) [LCF/BQ/PR20/11770008 to SW]; Instituto de Salud Carlos III (ISCIII) [PI18/00348 to VE]; ISCIII [PI21/01641 to RT-R]; Spanish National Research and Development Plan, ISCIII and FEDER [PI17/02303 and PI20/01837 to SR-P]; Proyecto Desarrollo Tecnológico [DTS19/00111 to SR-P], AEI/MICIU EXPLORA Project [BIO2017-91272-EXP to SR-P]; Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León (CCVC8485) [PID2019-104218RB-I00 to DB]; NIH [DK088199 to RB] and Universidad Complutense de Madrid (UCM 920631) [CT42/18-CT43/18 and EB15/21 to BM-A]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis

  • Wculek, Stefanie K
  • Heras-Murillo, Ignacio
  • Mastrangelo, Annalaura
  • Mañanes, Diego
  • Galán, Miguel
  • Miguel, Verónica
  • Curtabbi, Andrea
  • Barbas, Coral
  • Chandel, Navdeep S
  • Enríquez, José Antonio
  • Lamas Peláez, Santiago
  • Sancho, David
In vitro studies have associated oxidative phosphorylation (OXPHOS) with anti-inflammatory macrophages, whereas pro-inflammatory macrophages rely on glycolysis. However, the metabolic needs of macrophages in tissues (TMFs) to fulfill their homeostatic activities are incompletely understood. Here, we identified OXPHOS as the highest discriminating process among TMFs from different organs in homeostasis by analysis of RNA-seq data in both humans and mice. Impairing OXPHOS in TMFs via Tfam deletion differentially affected TMF populations. Tfam deletion resulted in reduction of alveolar macrophages (AMs) due to impaired lipid-handling capacity, leading to increased cholesterol content and cellular stress, causing cell-cycle arrest in vivo. In obesity, Tfam depletion selectively ablated pro-inflammatory lipid-handling white adipose tissue macrophages (WAT-MFs), thus preventing insulin resistance and hepatosteatosis. Hence, OXPHOS, rather than glycolysis, distinguishes TMF populations and is critical for the maintenance of TMFs with a high lipid-handling activity, including pro-inflammatory WAT-MFs. This could provide a selective therapeutic targeting tool., This project was supported by the “la Caixa” Foundation (ID 100010434) Postdoctoral Junior Leader Fellowship code LCF/BQ/PR20/11770008 (S.K.W.); “la Caixa” Foundation (ID 100010434) INPhINIT Fellowship code LCF/BQ/IN17/11620074 (I.H.-M.); Spanish Ministry of Education FPU fellowship code FPU20/01418 (M.G.); Ministerio de Ciencia e Innovación (MCIN) PID2019-104233RB-100/AEI/10.13039/501100011033 (S.L.); and NIH grants P01AG049665-08, RO1A148190, and P01HL154998 (N.S.C.). The J.A.E. laboratory is supported by the CNIC and a grant by Ministerio de Ciencia, Innovación y Universidades (MCNU); Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-099357-B-I00); the Biomedical Research Networking Center on Frailty and Healthy Ageing (CIBERFES-ISCiii-CB16/10/00289); and the HFSP agency (RGP0016/2018). Work in the D.S. laboratory is funded by the CNIC; by the European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator grant 725091; by Spanish Ministerio de Ciencia e Innovación PID2019-108157RB/AEI/ and CPP2021-008310/AEI/10.13039/501100011033; by Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); and by “la Caixa” Foundation (LCF/PR/HR20/00075 and LCF/PR/HR22/00253). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICINN, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung

  • Moreo, Eduardo
  • Jarit-Cabanillas, Aitor
  • Robles-Vera, Iñaki
  • Uranga, Santiago
  • Guerrero, Claudia
  • Gómez, Ana Belén
  • Mata-Martínez, Pablo
  • Minute, Luna
  • Araujo-Voces, Miguel
  • Felgueres, María José
  • Esteso, Gloria
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julián
  • Martín, Carlos
  • Valés-Gómez, Mar
  • Del Fresno, Carlos
  • Sancho, David
  • Aguiló, Nacho
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-023-41768-8., Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of BCG is well-tolerated and effective in preventing tuberculosis infection in animals. Here, we examine IV BCG in several preclinical lung tumor models. Our findings demonstrate that BCG inoculation reduced tumor growth and prolonged mouse survival in models of lung melanoma metastasis and orthotopic lung adenocarcinoma. Moreover, IV BCG treatment was well-tolerated with no apparent signs of acute toxicity. Mechanistically, IV BCG induced tumor-specific CD8+ T cell responses, which were dependent on type 1 conventional dendritic cells, as well as NK cell-mediated immunity. Lastly, we also show that IV BCG has an additive effect on anti-PD-L1 checkpoint inhibitor treatment in mouse lung tumors that are otherwise resistant to anti-PD-L1 as monotherapy. Overall, our study demonstrates the potential of systemic IV BCG administration in the treatment of lung tumors, highlighting its ability to enhance immune responses and augment immune checkpoint blockade efficacy., This work was supported by MCIN/AEI/10.13039/501100011033 [grants number RTI2018-097625-B-I00 and PID2022-138624OB-I00], Gobierno de Aragón [grant number LMP50_21] and Asociación Española Contra el Cáncer (AECC) [grant number IDEAS211042AGUI]. NA was the prin- cipal investigator of all these grants. This research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (Groups CB06/06/0020 and CB21/13/00087), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. DS laboratory is funded by the CNIC; by the European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; by MCIN PID2019-108157RB MCIN/AEI/10.13039/501100011033 and CPP2021- 008310 MCIN/AEI/10.13039/501100011033 Unión Europea Next Gen- erationEU/PRTR; by Comunidad de Madrid (P2022/BMD-7333 INMU- NOVAR-CM); and by “la Caixa” Foundation (LCF/PR/HR20/00075 and LCF/PR/HR22/00253).The laboratory of C.d.F. is funded by Instituto de Salud Carlos III (ISCIII) through the projects CP20/00106 and PI21/01178 and co-funded by the European Union. The laboratory of M.V-G. is fun- ded by Spanish Ministry of Science and Innovation [grant number PID2021-123795OB-I00]. C.G. has a pre-doctoral fellowship from Gobierno de Aragón. M.J.F. is PhD Candidate at the Autonomous Madrid University., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung

  • Moreo, Eduardo
  • Jarit-Cabanillas, Aitor
  • Robles-Vera, Iñaki
  • Uranga, Santiago
  • Guerrero, Claudia
  • Gómez, Ana Belén
  • Mata-Martínez, Pablo
  • Minute, Luna
  • Araujo-Voces, Miguel
  • Felgueres, María José
  • Esteso, Gloria
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julián
  • Martín, Carlos
  • Valés-Gómez, Mar
  • del Fresno, Carlos
  • Sancho, David
  • Aguiló, Nacho
Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of BCG is well-tolerated and effective in preventing tuberculosis infection in animals. Here, we examine IV BCG in several preclinical lung tumor models. Our findings demonstrate that BCG inoculation reduced tumor growth and prolonged mouse survival in models of lung melanoma metastasis and orthotopic lung adenocarcinoma. Moreover, IV BCG treatment was well-tolerated with no apparent signs of acute toxicity. Mechanistically, IV BCG induced tumor-specific CD8+ T cell responses, which were dependent on type 1 conventional dendritic cells, as well as NK cell-mediated immunity. Lastly, we also show that IV BCG has an additive effect on anti-PD-L1 checkpoint inhibitor treatment in mouse lung tumors that are otherwise resistant to anti-PD-L1 as monotherapy. Overall, our study demonstrates the potential of systemic IV BCG administration in the treatment of lung tumors, highlighting its ability to enhance immune responses and augment immune checkpoint blockade efficacy.